226 related articles for article (PubMed ID: 16445867)
1. Reduction in the risk of human breast cancer by selective cyclooxygenase-2 (COX-2) inhibitors.
Harris RE; Beebe-Donk J; Alshafie GA
BMC Cancer; 2006 Jan; 6():27. PubMed ID: 16445867
[TBL] [Abstract][Full Text] [Related]
2. Similar reductions in the risk of human colon cancer by selective and nonselective cyclooxygenase-2 (COX-2) inhibitors.
Harris RE; Beebe-Donk J; Alshafie GA
BMC Cancer; 2008 Aug; 8():237. PubMed ID: 18702823
[TBL] [Abstract][Full Text] [Related]
3. Reduced risk of human lung cancer by selective cyclooxygenase 2 (COX-2) blockade: results of a case control study.
Harris RE; Beebe-Donk J; Alshafie GA
Int J Biol Sci; 2007 Jun; 3(5):328-34. PubMed ID: 17589567
[TBL] [Abstract][Full Text] [Related]
4. Cyclooxygenase-2 (cox-2) blockade in the chemoprevention of cancers of the colon, breast, prostate, and lung.
Harris RE
Inflammopharmacology; 2009 Apr; 17(2):55-67. PubMed ID: 19340409
[TBL] [Abstract][Full Text] [Related]
5. Low-dose Aspirin, Nonsteroidal Anti-inflammatory Drugs, Selective COX-2 Inhibitors and Breast Cancer Recurrence.
Cronin-Fenton DP; Heide-Jørgensen U; Ahern TP; Lash TL; Christiansen P; Ejlertsen B; Sørensen HT
Epidemiology; 2016 Jul; 27(4):586-93. PubMed ID: 27007644
[TBL] [Abstract][Full Text] [Related]
6. Cancer chemoprevention by cyclooxygenase 2 (COX-2) blockade: results of case control studies.
Harris RE; Beebe-Donk J; Alshafie GA
Subcell Biochem; 2007; 42():193-212. PubMed ID: 17612052
[TBL] [Abstract][Full Text] [Related]
7. Association between frequent use of nonsteroidal anti-inflammatory drugs and breast cancer.
Rahme E; Ghosn J; Dasgupta K; Rajan R; Hudson M
BMC Cancer; 2005 Dec; 5():159. PubMed ID: 16343343
[TBL] [Abstract][Full Text] [Related]
8. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction.
Gislason GH; Jacobsen S; Rasmussen JN; Rasmussen S; Buch P; Friberg J; Schramm TK; Abildstrom SZ; Køber L; Madsen M; Torp-Pedersen C
Circulation; 2006 Jun; 113(25):2906-13. PubMed ID: 16785336
[TBL] [Abstract][Full Text] [Related]
9. Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study.
Rahme E; Nedjar H
Rheumatology (Oxford); 2007 Mar; 46(3):435-8. PubMed ID: 17255138
[TBL] [Abstract][Full Text] [Related]
10. Prescription channeling of COX-2 inhibitors and traditional nonselective nonsteroidal anti-inflammatory drugs: a population-based case-control study.
Moride Y; Ducruet T; Boivin JF; Moore N; Perreault S; Zhao S
Arthritis Res Ther; 2005; 7(2):R333-42. PubMed ID: 15743481
[TBL] [Abstract][Full Text] [Related]
11. Selective cyclooxygenase-2 (COX-2) inhibitors and breast cancer risk.
Ashok V; Dash C; Rohan TE; Sprafka JM; Terry PD
Breast; 2011 Feb; 20(1):66-70. PubMed ID: 20724158
[TBL] [Abstract][Full Text] [Related]
12. Association of frequency and duration of aspirin use and hormone receptor status with breast cancer risk.
Terry MB; Gammon MD; Zhang FF; Tawfik H; Teitelbaum SL; Britton JA; Subbaramaiah K; Dannenberg AJ; Neugut AI
JAMA; 2004 May; 291(20):2433-40. PubMed ID: 15161893
[TBL] [Abstract][Full Text] [Related]
13. What happened to the prescribing of other COX-2 inhibitors, paracetamol and non-steroidal anti-inflammatory drugs when rofecoxib was withdrawn in Australia?
Barozzi N; Tett SE
Pharmacoepidemiol Drug Saf; 2007 Nov; 16(11):1184-91. PubMed ID: 17636557
[TBL] [Abstract][Full Text] [Related]
14. What have we learned from the large outcomes trials of COX-2 selective inhibitors? The rheumatologist's perspective.
Hochberg MC
Clin Exp Rheumatol; 2001; 19(6 Suppl 25):S15-22. PubMed ID: 11695246
[TBL] [Abstract][Full Text] [Related]
15. Prescriptions for selective cyclooxygenase-2 inhibitors, non-selective non-steroidal anti-inflammatory drugs, and risk of breast cancer in a population-based case-control study.
Cronin-Fenton DP; Pedersen L; Lash TL; Friis S; Baron JA; Sørensen HT
Breast Cancer Res; 2010; 12(2):R15. PubMed ID: 20193065
[TBL] [Abstract][Full Text] [Related]
16. Utilization of non-steroidal anti-inflammatory drugs in Quebec: adherence to the Canadian consensus on prescription guidelines.
Moride Y; Ducruet T; Boivin JF; Lavoie F; Rochon S
Can J Clin Pharmacol; 2005; 12(2):e201-11. PubMed ID: 15998959
[TBL] [Abstract][Full Text] [Related]
17. Hospitalization for peptic ulcer and bleeding in users of selective COX-2 inhibitors and nonselective NSAIDs with special reference to celecoxib.
Patterson MK; Castellsague J; Walker AM
Pharmacoepidemiol Drug Saf; 2008 Oct; 17(10):982-8. PubMed ID: 18711705
[TBL] [Abstract][Full Text] [Related]
18. Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs: high-risk subgroups and time course of risk.
Solomon DH; Avorn J; Stürmer T; Glynn RJ; Mogun H; Schneeweiss S
Arthritis Rheum; 2006 May; 54(5):1378-89. PubMed ID: 16645966
[TBL] [Abstract][Full Text] [Related]
19. Risk of upper gastrointestinal complications associated with cyclooxygenase-2 selective and nonselective nonsteroidal antiinflammatory drugs.
Castellsague J; Holick CN; Hoffman CC; Gimeno V; Stang MR; Perez-Gutthann S
Pharmacotherapy; 2009 Dec; 29(12):1397-407. PubMed ID: 19947799
[TBL] [Abstract][Full Text] [Related]
20. The use and safety profile of non-steroidal antiinflammatory drugs among Turkish patients with osteoarthritis.
Yilmaz H; Gürel S; Ozdemir O
Turk J Gastroenterol; 2005 Sep; 16(3):138-42. PubMed ID: 16245223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
